(OA19) Low-Dose-Rate Brachytherapy as Monotherapy for High-Risk Prostate Cancer: 15-Year Outcomes Data

In this study we aimed to examine long-term biochemical control and survival with low-dose-rate brachytherapy (LDR-BT) alone for HRPC.

Source: International Journal of Radiation Oncology * Biology * Physics - May 3, 2018 Category: Radiology Authors: Stanislav Lazarev, Jerry Liu, Marcher Thompson, Zahra Ghiassi, Nelson N. Stone, Richard G. Stock Tags: Oral Abstract Source Type: research